Jefferies analyst Brian Abrahams raised his price target for Celgene shares to $155 from $147 following a "deep dive" into the company's "many partnerships." The stock closed yesterday up $3.55 to $121.78. In a research note titled "Hidden Treasures: Deep Dive Shows Partnerships Could Unlock Significant Value," Abrahams says the Street is underestimating the "diversity, promise, and potential" of Celgene's partnerships. He sees the deals driving long-term growth, even post-Revlimid cliff. Excluding academia, the analyst estimates Celgene has 35-plus active collaborations. He keeps a Buy rating on the shares.